{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:04:07Z","timestamp":1784811847782,"version":"3.55.0"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["A&amp;D Transl Res &amp; Clin Interv"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>In the realm of medical research, assessing novel therapies extends beyond statistical significance. The concept of meaningful benefits plays a pivotal role in determining the practical impact of interventions on patient outcomes. Clinical trials, which form the bedrock of evidence\u2010based medicine, guide treatment decisions and shape health\u2010care practices. While statistical significance remains a fundamental criterion, it falls short in fully evaluating the clinical relevance of therapeutic interventions. Clinically meaningful benefits focus on tangible improvements in patient health and well\u2010being, transcending mere statistical thresholds. Key considerations include survival rates, symptom relief, functional status, and other patient\u2010oriented outcomes. Determining meaningful benefits varies across diseases, patient populations, and available treatments. Balancing statistical rigor with clinical relevance is crucial. Overpowered trials may detect smaller differences than anticipated, necessitating careful interpretation. Researchers must view trial results through a patient\u2010centric lens. Beyond survival, evaluating quality of life and side effects is equally relevant. Quantifying meaningful benefits involves metrics like numbers needed to treat and progression\u2010free survival. Consistency across outcomes matters, as clinicians weigh gains in survival against improvements in quality of life. The pursuit of meaningful benefits elevates clinical trials from mere statistical exercises to patient\u2010centered endeavors. Researchers, clinicians, and regulators must prioritize outcomes that genuinely matter to patients, ensuring that medical progress translates into meaningful improvements for them and their families.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/trc2.70090","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T02:49:40Z","timestamp":1745549380000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinically meaningful benefit and real\u2010world evidence in Alzheimer's disease research and care"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1981-7435","authenticated-orcid":false,"given":"Robert","family":"Perneczky","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy University Hospital, LMU Munich  Munich Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) Munich  Munich Germany"},{"name":"Munich Cluster for Systems Neurology (SyNergy)  Munich Germany"},{"name":"Ageing Epidemiology (AGE) Research Unit, School of Public Health Imperial College London  London UK"},{"name":"Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Froelich","sequence":"additional","affiliation":[{"name":"Department of Geriatric Psychiatry Central Institute of Mental Health  Mannheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.18496"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12959"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00659-6"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.8009"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky039"},{"key":"e_1_2_10_7_1","first-page":"108","article-title":"The power of \u201cp\u201d: on overpowered clinical trials and \u201cpositive\u201d results","volume":"2","author":"Hochster HS","year":"2008","journal-title":"Gastrointest Cancer Res"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.3508"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2021-000877"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.6338589"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"e_1_2_10_12_1","unstructured":"LeberP.FDA guidelines for the clinical evaluation of antidementia drugs. First draft.1990. doi:10.13140\/2.1.4164.9445"},{"key":"e_1_2_10_13_1","first-page":"105","article-title":"Function and clinical meaningfulness of treatments for mild Alzheimer's disease","volume":"2","author":"Siemers E","year":"2016","journal-title":"Alzheimers Dement"},{"key":"e_1_2_10_14_1","volume-title":"Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease","author":"US Food and Drug Administration (FDA)","year":"2013"},{"key":"e_1_2_10_15_1","volume-title":"Guideline on the Clinical Investigation of Medicines for the Treatment of Alzheimer's Disease\u2014Revision 2","author":"European Medicines Agency (EMA)","year":"2018"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2019.30"},{"key":"e_1_2_10_17_1","volume-title":"Early Alzheimer's disease: developing drugs for treatment (Draft guidance)","author":"US Food and Drug Administration","year":"2024"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12465"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-00984-y"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.13128"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad005"},{"key":"e_1_2_10_23_1","article-title":"Cost\u2010effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price","volume":"8","author":"Sinha P","year":"2022","journal-title":"Alzheimers Dement"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.3061"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2412-a"},{"key":"e_1_2_10_27_1","first-page":"227","article-title":"A combined measure of cognition and function for clinical trials: the integrated Alzheimer's disease rating scale (iADRS)","volume":"2","author":"Wessels AM","year":"2015","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.06.005"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.102"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.24406"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.123"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01024-z"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-3774-6_2"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40359-023-01319-8"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100096"}],"container-title":["Alzheimer's &amp; Dementia: Translational Research &amp; Clinical Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/trc2.70090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T09:24:04Z","timestamp":1761470644000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/trc2.70090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/trc2.70090"],"URL":"https:\/\/doi.org\/10.1002\/trc2.70090","archive":["Portico"],"relation":{},"ISSN":["2352-8737","2352-8737"],"issn-type":[{"value":"2352-8737","type":"print"},{"value":"2352-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-08-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70090"}}